Does This Hostile Takeover Make Sense?

The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson and consumer goods editor/analyst Austin Smith discuss topics across the investing world.

Acquisitions are all the rage in the health-care sector these days, and Roche just made waves with its hostile takeover targeting a prominent gene sequencing company. In this video, David and Austin discuss whether Roche's first offer will be enough to get the deal done and if jumping into gene sequencing companies make sense for Roche or investors.

Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report: "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.

At the time thisarticle was published Austin Smith and David Williamson have no positions in the stocks mentioned above. The Motley Fool owns shares of Abbott Laboratories.Motley Fool newsletter services recommendIllumina. Try any of our Foolish newsletter servicesfree for 30 days. We Fools may not all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.